朱涤潮,张 涛,张明辉.MMR/MSI在结直肠癌抗PD-1/PD-L1免疫检查点治疗中的作用[J].肿瘤学杂志,2017,23(10):904-909. |
MMR/MSI在结直肠癌抗PD-1/PD-L1免疫检查点治疗中的作用 |
The Role of MMR/MSI in Anti-PD-1/PD-L1 Immune Checkpoint Therapy for Colorectal Cancer |
投稿时间:2016-12-16 |
DOI:10.11735/j.issn.1671-170X.2017.10.B014 |
|
|
中文关键词: MMR 结直肠癌 PD-1/PD-L1 免疫治疗 |
英文关键词:MMR colorectal cancer PD-1/PD-L1 immunotherapy |
基金项目: |
|
摘要点击次数: 2279 |
全文下载次数: 543 |
中文摘要: |
摘 要:随着免疫检测点抑制剂类药物研究的深入,研究发现抗PD-1/PD-L1 抑制剂仅在部分患者中获得良好的疗效,寻找可靠的生物标记以区别出可获益的人群是免疫治疗能否更好应用于临床的关键。抗 PD-1/PD-L1 免疫治疗的潜在预测标志物是从肿瘤细胞、免疫细胞以及各种细胞因子的生物学特性和彼此之间相互作用中寻找,目前研究最多的有PD-L2、TILs、IFN-γ、BIM、免疫评分、体细胞基因突变的负荷和MMR基因缺失等。全文就MMR基因缺失在结直肠癌抗PD-1/PD-L1 免疫治疗疗效预测中作用作一综述。 |
英文摘要: |
Abstract:With the development of clinical studies of immunosuppressive point inhibitors,it has been found that anti-PD-1/PD-L1 inhibitors were effective only in some patients. The search for reliable biomarkers to differentiate between those who can benefit was the key to whether immunotherapy can be better used clinically. The potential predictive markers of anti-PD-1/PD-L1 immunotherapy were tumor cells,immune cells and various cytokines,and the most common were:PD-L2,TILs,IFN-γ,BIM,immune score,somatic gene mutation load and MMR gene deletion.. The role of MMR gene deletion in predicting the efficacy of anti-PD-1/PD-L1 immunotherapy in colorectal cancer was discussed in this paper. |
在线阅读
查看全文 查看/发表评论 下载PDF阅读器 |